文献速递前列腺癌

雄激素受体信号抑制剂联合多西他赛及雄激素剥夺治疗转移性激素敏感性前列腺癌:系统评价与Meta分析

Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol · 2022-08-19

该系统评价与网络Meta分析纳入11项随机对照试验,分析雄激素受体信号抑制剂(ARSI)联合多西他赛(DOC)及雄激素剥夺治疗(ADT)三药方案对比现有方案在转移性激素敏感性前列腺癌(mHSPC)中的生存获益。三药方案在总生存(OS)和无进展生存(PFS)上优于DOC+ADT,且在网络比较中优于ARSI+ADT。作者认为三药方案改善生存终点,但需进一步头对头试验及更长随访确认。

要点

  • 三药方案对比DOC+ADT:OS合并HR 0.74(95%CI 0.65-0.84),PFS合并HR 0.49(95%CI 0.42-0.58)。
  • 低瘤负荷与高瘤负荷患者从DOC+ADT加用ARSI的OS获益无统计学显著差异(两组HR均为0.79,p=1)。
  • 网络Meta分析中三药方案对比ARSI+ADT:OS(DAR+DOC+ADT)合并HR 0.74(95%CI 0.55-0.99);PFS(ABI+DOC+ADT)HR 0.68(95%CI 0.51-0.91),(ENZ+DOC+ADT)HR 0.70(95%CI 0.53-0.93)。

核心结论

  • 三药联合方案对比现有双药方案改善mHSPC患者的生存终点(OS与PFS)。
  • 作者指出该发现需在进一步头对头试验中、更长随访及不同患者人群中确认。

研究设计与样本

  • 系统评价与Meta分析,检索三个数据库及会议摘要(2022年4月),纳入11项随机对照试验。
  • 主要结局指标为总生存(OS)和无进展生存(PFS),并进行低/高瘤负荷及原发/异时转移亚组分析。
  • 同时进行网络Meta分析(NMA)及治疗排名分析。

主要发现

  • 三药方案对比DOC+ADT:OS合并HR 0.74(95%CI 0.65-0.84),PFS合并HR 0.49(95%CI 0.42-0.58)。
  • 低瘤负荷与高瘤负荷患者从DOC+ADT加用ARSI的OS获益无统计学显著差异(两组HR均为0.79,p=1)。
  • 网络Meta分析中三药方案对比ARSI+ADT:OS(DAR+DOC+ADT)合并HR 0.74(95%CI 0.55-0.99)。
  • 网络Meta分析中三药方案对比ARSI+ADT:PFS(ABI+DOC+ADT)HR 0.68(95%CI 0.51-0.91),(ENZ+DOC+ADT)HR 0.70(95%CI 0.53-0.93)。
  • 原发mHSPC患者治疗排名分析显示,高瘤负荷患者三药方案改善OS的可能性最高,低瘤负荷患者ARSI+ADT双药方案改善OS的可能性最高。

局限性

  • 作者指出该发现需在进一步头对头试验中确认。
  • 作者指出需更长随访。
  • 作者指出需在不同患者人群中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Recent randomized controlled trials (RCTs) examined the role of adding androgen receptor signaling inhibitors (ARSIs), including abiraterone acetate (ABI), apalutamide, darolutamide (DAR), and enzalutamide (ENZ), to docetaxel (DOC) and androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). OBJECTIVE: To analyze the oncologic benefit of triplet combination therapies using ARSI + DOC + ADT, and comparing them with available treatment regimens in patients with mHSPC. EVIDENCE ACQUISITION: Three databases and meetings abstracts were queried in April 2022 for RCTs analyzing patients treated with first-line combination systemic therapy for mHSPC. The primary interests of measure were overall survival (OS) and progression-free survival (PFS). Subgroup analyses were conducted to assess the differential outcomes in patients with low- and high-volume disease as well as de novo and metachronous metastasis. EVIDENCE SYNTHESIS: Overall, 11 RCTs were included for meta-analyses and network meta-analyses (NMAs). We found that the triplet combinations outperformed DOC + ADT in terms of OS (pooled hazard ratio [HR]: 0.74, 95% confidence interval [CI]: 0.65-0.84) and PFS (pooled HR: 0.49, 95% CI: 0.42-0.58). There was no statistically significant difference between patients with low- and high-volume disease in terms of an OS benefit from adding an ARSI to DOC +ADT (both HR: 0.79; p = 1). Based on NMAs, triplet therapy also outperformed ARSI + ADT in terms of OS (DAR + DOC + ADT: pooled HR: 0.74, 95% CI: 0.55-0.99) and PFS (ABI + DOC + ADT: HR: 0.68, 95% CI: 0.51-0.91, and ENZ + DOC + ADT: HR: 0.70, 95% CI: 0.53-0.93). An analysis of treatment ranking among de novo mHSPC patients showed that triplet therapy had the highest likelihood of improved OS in patients with high-volume disease; however, doublet therapy using ARSI + ADT had the highest likelihood of improved OS in patients with low-volume disease. CONCLUSIONS: We found that the triplet combination therapy improves survival endpoints in mHSPC patients compared with currently available doublet treatment regimens. Our findings need to be confirmed in further head-to-head trials with longer follow-up and among various patient populations. PATIENT SUMMARY: Our study suggests that triplet therapy with androgen receptor signaling inhibitor, docetaxel, androgen deprivation therapy prolongs survival in patients with metastatic hormone-sensitive prostate cancer compared with the current standard doublet therapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Yanagisawa T, Rajwa P, Thibault C, et al. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2022. PMID: 35995644. doi:10.1016/j.eururo.2022.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。